Please select the eligibility criteria that correspond to the clinical trial below.
Title: Treatment of Nephrotic Syndrome Relapse With Low Steroid Dose
Brief Summary: Background- Idiopathic Nephrotic syndrome is the common glomerular disease in childhood. conventional treatment is steroid treatment and nearly 90% response to this treatment well.

Response to this treatment is the most important prognostic factor and this patients has a benign disease course.

60-70% among patients that response to steroid treatment,will suffer a relapse of NS.repeated steroids courses can lead to serious adverse events in children such as low bone density,weight gain ,growth slow down ,elevated blood pressure and eye pressure.there is side effect corelation between steroid dose and treatment duration.

guidelines for steroid dose for NS relapse are not based on retrospective clinical research but only on Nephrologists and experts opinion.

Rational- What would be the optimal low dose steroids and the shortest time of treatment in Nephrotic syndrome relapse?


Options:
A: Inclusion Criteria:

* newly presenting nephrotic syndrome, urine albumin/protein creatinine ratio \>200mg/mmol on early morning urine sample, hypoalbuminemia (\<25g/L)

Exclusion Criteria:

* prior treatment with steroids or cytotoxic agents underlying systemic disorder or exposure to agents known to be associated with newly presenting steroid sensitive nephrotic syndrome
B: Inclusion Criteria:

* Male or female 18 - 65 years of age
* First histologic diagnosis of MCNS
* Proteinuria \> 3.5 g/day
* Patients who are willing to give written, informed consent

Exclusion Criteria:

* Presence of secondary causes of MCNS
* History of glomerular disease including MCNS
* eGFR \< 50 ml/min/1.73m2
* Renal histology showing pathologies other than MCNS
* Female of child-bearing age who are unwilling to practice effective contraception
* Patients simultaneously participating in another study or who have participated in another study within the last 30 days of entry into this study
C: Inclusion Criteria:

1. Idiopathic, steroid-sensitive, first episode of nephrotic syndrome
2. Age 12 months up to 48 months
3. Written informed consent

Exclusion Criteria

1. Nephrotic syndrome known to be secondary to a systemic disorder, e.g., Immunoglobulin A (IgA) nephropathy, systemic lupus erythematosus, Henoch Schonlein purpura, vasculitis, , hepatitis B or Alport syndrome.
2. Persistent estimated glomerular filtration rate (GFR) \<75 ml/min/1.73 m2,
3. Therapy with prednisolone for prior episodes of nephrotic syndrome,
4. Therapy with corticosteroids in the past 3 months, in a dose more than 1 mg/kg for \>14 days for any other reason,
5. Corticosteroid therapy for initial episode of nephrotic syndrome prior to randomization varying from pre-specified protocol on more than 14 days,
6. Patients who show relapse during the first 3 months of pre-randomization corticosteroid therapy for nephrotic syndrome,
7. Unclear treatment history,
8. Gross hematuria,
9. Patients with initial steroid resistance,
10. Participation in any other drug study during the course of this study.
11. Participation in more than one study without approval from the researchers involved in each study,
D: Inclusion Criteria:

* Patients with Idiopathic nephrotic syndrome with a flair that needs steroids treatment.

Exclusion Criteria:

* Steroid resistance or treatment with Cyclosporin or Cellcept

Answer: D